- Home
- RM vs THRD Comparison
RM vs THRD Comparison
Compare RM & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RM
- THRD
- Stock Information
- Founded
- RM 1987
- THRD 2019
- Country
- RM United States
- THRD United States
- Employees
- RM N/A
- THRD N/A
- Industry
- RM Finance: Consumer Services
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- RM Finance
- THRD Health Care
- Exchange
- RM Nasdaq
- THRD Nasdaq
- Market Cap
- RM 282.1M
- THRD 232.4M
- IPO Year
- RM 2012
- THRD 2022
- Fundamental
- Price
- RM $26.60
- THRD $5.22
- Analyst Decision
- RM Hold
- THRD Hold
- Analyst Count
- RM 3
- THRD 3
- Target Price
- RM $30.00
- THRD $5.00
- AVG Volume (30 Days)
- RM 50.3K
- THRD 310.5K
- Earning Date
- RM 07-30-2025
- THRD 05-08-2025
- Dividend Yield
- RM 4.54%
- THRD N/A
- EPS Growth
- RM 41.13
- THRD N/A
- EPS
- RM 3.29
- THRD N/A
- Revenue
- RM $577,647,000.00
- THRD N/A
- Revenue This Year
- RM $13.10
- THRD N/A
- Revenue Next Year
- RM $9.35
- THRD N/A
- P/E Ratio
- RM $8.03
- THRD N/A
- Revenue Growth
- RM 6.45
- THRD N/A
- 52 Week Low
- RM $25.41
- THRD $3.18
- 52 Week High
- RM $37.52
- THRD $16.02
- Technical
- Relative Strength Index (RSI)
- RM 33.92
- THRD 73.54
- Support Level
- RM $26.16
- THRD $5.16
- Resistance Level
- RM $27.01
- THRD $5.22
- Average True Range (ATR)
- RM 0.71
- THRD 0.04
- MACD
- RM -0.15
- THRD -0.04
- Stochastic Oscillator
- RM 0.00
- THRD 90.00
About RM Regional Management Corp.
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.